0 9 Increased increase VBN 10 17 IkappaB IkappaB NNP 18 28 expression expression NN 29 32 and and CC 33 43 diminished diminish VBD 44 51 nuclear nuclear JJ 52 61 NF-kappaB nf-kappab NN 62 64 in in IN 65 70 human human JJ 71 82 mononuclear mononuclear JJ 83 88 cells cell NNS 89 98 following follow VBG 99 113 hydrocortisone hydrocortisone NN 114 123 injection injection NN 123 124 . . . 126 128 We we PRP 129 133 have have VBP 134 142 recently recently RB 143 155 demonstrated demonstrate VBN 156 160 that that IN 161 175 hydrocortisone hydrocortisone NN 176 179 and and CC 180 185 other other JJ 186 201 glucocorticoids glucocorticoid NNS 202 209 inhibit inhibit VBP 210 218 reactive reactive JJ 219 225 oxygen oxygen NN 226 233 species specie NNS 234 235 ( ( ( 235 238 ROS ROS NNP 238 239 ) ) ) 240 250 generation generation NN 251 253 by by IN 254 265 mononuclear mononuclear JJ 266 267 ( ( ( 267 270 MNC MNC NNP 270 271 ) ) ) 272 275 and and CC 276 293 polymorphonuclear polymorphonuclear JJ 294 304 leucocytes leucocyte NNS 305 306 ( ( ( 306 310 PMNL PMNL NNP 310 311 ) ) ) 311 312 . . . 313 318 Since since IN 319 336 NF-kappaB/IkappaB NF-kappaB/IkappaB NNP 337 343 system system NN 344 353 regulates regulate VBZ 354 357 the the DT 358 371 transcription transcription NN 372 374 of of IN 375 390 proinflammatory proinflammatory JJ 391 396 genes gene NNS 396 397 , , , 398 407 including include VBG 408 413 those those DT 414 425 responsible responsible JJ 426 429 for for IN 430 433 ROS ROS NNP 434 444 generation generation NN 444 445 , , , 446 448 we we PRP 449 455 tested test VBD 456 459 the the DT 460 470 hypothesis hypothesis NN 471 475 that that IN 476 490 hydrocortisone hydrocortisone NN 491 494 may may MD 495 504 stimulate stimulate VB 505 512 IkappaB IkappaB NNP 513 523 production production NN 524 528 thus thus RB 529 539 inhibiting inhibit VBG 540 549 NF-kappaB NF-kappaB NNP 550 563 translocation translocation NN 564 568 from from IN 569 572 the the DT 573 580 cytosol cytosol NN 581 585 into into IN 586 589 the the DT 590 597 nucleus nucleus NN 598 600 in in IN 601 604 MNC MNC NNP 604 605 , , , 606 608 in in FW 609 613 vivo vivo FW 613 614 . . . 615 618 One one CD 619 626 hundred hundred CD 627 636 milligram milligram NN 637 639 of of IN 640 654 hydrocortisone hydrocortisone NN 655 658 was be VBD 659 667 injected inject VBN 668 681 intravenously intravenously RB 682 686 into into IN 687 688 4 4 CD 689 695 normal normal JJ 696 704 subjects subject NNS 704 705 . . . 706 711 Blood Blood NNP 712 719 samples sample NNS 720 724 were be VBD 725 733 obtained obtain VBN 734 739 prior prior RB 740 742 to to TO 743 746 the the DT 747 756 injection injection NN 757 760 and and CC 761 763 at at IN 764 765 1 1 CD 765 766 , , , 767 768 2 2 CD 768 769 , , , 770 771 4 4 CD 771 772 , , , 773 774 8 8 CD 775 778 and and CC 779 781 24 24 CD 782 784 hr hr NN 785 790 after after IN 791 794 the the DT 795 804 injection injection NN 804 805 . . . 806 813 Nuclear nuclear JJ 814 822 extracts extract NNS 823 826 and and CC 827 832 total total JJ 833 837 cell cell NN 838 845 lysates lysate NNS 846 850 were be VBD 851 859 prepared prepare VBN 860 864 from from IN 865 868 MNC MNC NNP 869 871 by by IN 872 880 standard standard JJ 881 891 techniques technique NNS 891 892 . . . 893 900 IkappaB IkappaB NNP 901 907 levels level NNS 908 910 in in IN 911 914 MNC MNC NNP 915 926 homogenates homogenate NNS 927 936 increased increase VBD 937 939 at at IN 940 941 1 1 CD 942 944 hr hr NN 944 945 , , , 946 952 peaked peak VBD 953 955 at at IN 956 959 2-4 2-4 CD 960 962 hr hr NN 962 963 , , , 964 971 started start VBD 972 974 to to TO 975 983 decrease decrease VB 984 986 at at IN 987 988 8 8 CD 989 991 hr hr NN 991 992 , , , 993 996 and and CC 997 1005 returned return VBD 1006 1008 to to TO 1009 1017 baseline baseline NN 1018 1024 levels level NNS 1025 1027 at at IN 1028 1030 24 24 CD 1031 1034 hr. hr. NN 1035 1044 NF-kappaB nf-kappab NN 1045 1047 in in IN 1048 1051 MNC MNC NNP 1052 1059 nuclear nuclear JJ 1060 1068 extracts extract NNS 1069 1078 decreased decrease VBD 1079 1081 at at IN 1082 1083 1 1 CD 1084 1086 hr hr NN 1086 1087 , , , 1088 1095 reached reach VBD 1096 1097 a a DT 1098 1103 nadir nadir NN 1104 1106 at at IN 1107 1108 4 4 CD 1109 1111 hr hr NN 1111 1112 , , , 1113 1122 gradually gradually RB 1123 1132 increased increase VBD 1133 1135 at at IN 1136 1137 8 8 CD 1138 1140 hr hr NN 1141 1144 and and CC 1145 1153 returned return VBD 1154 1158 back back RB 1159 1161 to to TO 1162 1170 baseline baseline NN 1171 1177 levels level NNS 1178 1180 at at IN 1181 1183 24 24 CD 1184 1186 hr hr NN 1186 1187 . . . 1188 1191 The the DT 1192 1197 total total JJ 1198 1205 protein protein NN 1206 1213 content content NN 1214 1216 of of IN 1217 1226 NF-kappaB NF-kappaB NNP 1227 1234 subunit subunit NN 1235 1236 ( ( ( 1236 1239 P65 P65 NNP 1239 1240 ) ) ) 1241 1243 in in IN 1244 1247 MNC MNC NNP 1248 1255 lysates lysate NNS 1256 1260 also also RB 1261 1267 showed show VBD 1268 1269 a a DT 1270 1278 decrease decrease NN 1279 1288 following follow VBG 1289 1303 hydrocortisone hydrocortisone NN 1304 1313 injection injection NN 1313 1314 . . . 1315 1319 This this DT 1320 1328 decrease decrease NN 1329 1332 was be VBD 1333 1341 observed observe VBN 1342 1344 at at IN 1345 1346 2 2 CD 1347 1349 hr hr NN 1349 1350 , , , 1351 1358 reached reach VBD 1359 1360 a a DT 1361 1366 nadir nadir NN 1367 1369 at at IN 1370 1371 4 4 CD 1372 1374 hr hr NN 1374 1375 , , , 1376 1379 and and CC 1380 1388 returned return VBD 1389 1391 to to TO 1392 1400 baseline baseline NN 1401 1407 levels level NNS 1408 1410 at at IN 1411 1413 24 24 CD 1414 1417 hr. hr. NN 1418 1421 ROS ROS NNP 1422 1432 generation generation NN 1433 1443 inhibition inhibition NN 1444 1454 paralleled parallel VBD 1455 1464 NF-kappaB NF-kappaB NNP 1465 1471 levels level NNS 1472 1474 in in IN 1475 1478 the the DT 1479 1486 nucleus nucleus NN 1486 1487 . . . 1488 1490 It it PRP 1491 1494 was be VBD 1495 1504 inhibited inhibit VBN 1505 1507 at at IN 1508 1509 1 1 CD 1510 1512 hr hr NN 1512 1513 , , , 1514 1521 reached reach VBD 1522 1523 a a DT 1524 1529 nadir nadir NN 1530 1532 at at IN 1533 1536 2-4 2-4 CD 1537 1539 hr hr NN 1539 1540 , , , 1541 1548 started start VBD 1549 1551 to to TO 1552 1560 increase increase VB 1561 1563 at at IN 1564 1565 8 8 CD 1566 1568 hr hr NN 1568 1569 , , , 1570 1573 and and CC 1574 1582 returned return VBD 1583 1585 to to TO 1586 1591 basal basal JJ 1592 1598 levels level NNS 1599 1601 at at IN 1602 1604 24 24 CD 1605 1607 hr hr NN 1607 1608 . . . 1609 1612 Our our PRP$ 1613 1617 data datum NNS 1618 1629 demonstrate demonstrate VBP 1630 1634 that that IN 1635 1649 hydrocortisone hydrocortisone NN 1650 1657 induces induce VBZ 1658 1665 IkappaB IkappaB NNP 1666 1669 and and CC 1670 1680 suppresses suppress VBZ 1681 1690 NF-kappaB NF-kappaB NNP 1691 1701 expression expression NN 1702 1704 in in IN 1705 1708 MNC MNC NNP 1709 1711 in in IN 1712 1720 parallel parallel NN 1720 1721 . . . 1722 1729 IkappaB IkappaB NNP 1730 1737 further further RBR 1738 1745 reduces reduce VBZ 1746 1749 the the DT 1750 1763 translocation translocation NN 1764 1766 of of IN 1767 1776 NF-kappaB NF-kappaB NNP 1777 1781 into into IN 1782 1785 the the DT 1786 1793 nucleus nucleus NN 1794 1798 thus thus RB 1799 1809 preventing prevent VBG 1810 1813 the the DT 1814 1824 expression expression NN 1825 1827 of of IN 1828 1843 proinflammatory proinflammatory JJ 1844 1849 genes gene NNS 1849 1850 . . .